Area of research
Genetics · Molecular Biology
Research interest
Research interests include Inflammatory Bowel Disease, Gut microbiota and health, Microscopic Colitis, and Adolescent and Pediatric Healthcare.
Using machine learning to predict clinical remission with exclusive enteral nutrition in pediatric Crohn disease.
Microbes and Macrophages: How They Interact to Promote Ulcerative Colitis.
Early intestinal ultrasound findings predict remission and treatment response at 1 year in pediatric Crohn's disease.
Early proactive therapeutic drug monitoring with ustekinumab therapy in pediatric Crohn's disease: data from the prospective Canadian children IBD network.
Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort.
Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk.
European Crohn’s and Colitis Organisation consensus on dietary management of inflammatory bowel disease
Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
European Crohn's and Colitis Organisation consensus on dietary management of inflammatory bowel disease.
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Network analysis of extraintestinal manifestations and associated autoimmune disorders in Crohn’s disease and ulcerative colitis
Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.
Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization.
Modified Crohn's Disease Exclusion Diet Maintains Remission in Pediatric Crohn's Disease: Randomized Controlled Trial.
Neutrophil-to-Lymphocyte Ratio at Diagnosis Predicts Colonoscopic Activity in Pediatric Inflammatory Bowel Diseases.
Gut Microbial Signatures in Pediatric Crohn's Disease Vary According to Disease Activity Measures and Are Influenced by Proxies of Gastrointestinal Transit Time: An ImageKids Study.
Early childhood adiposity, lifestyle and gut microbiome are linked to steatotic liver disease development in adolescents.
Fiber Intervention Study in Prader-Willi Syndrome: Insights into Metabolic and Microbiota Shifts.
Rhomboid protease GlpG regulates type 1 pili quality control and virulence in pathogenic E. coli.
Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn's Disease and Ulcerative Colitis-An International Meta-Analysis.
Microbe-Activated Intestinal Drug Delivery for IBD.
Metagenome-Informed Metaproteomics: A New Frontier in Gut Host-Microbe-Diet Analysis.
Novel Immune Manipulators for IBD: Miniproteins!
The Impact of Integrating Pelvic Magnetic Resonance Imaging at Diagnosis on Early Detection of Perianal Crohn's Disease in Pediatrics.
The Crohn's Disease Exclusion Diet: A Comprehensive Review of Evidence, Implementation Strategies, Practical Guidance, and Future Directions.
Cultural Perspectives on the Efficacy and Adoption of the Crohn's Disease Exclusion Diet across Diverse Ethnicities: A Case-Based Overview.
Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
Response to FDA draft guidance on pediatric IBD drug approval trials: A consensus statement from the IBD Porto Group
Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.